Interim consolidated results: Revenue 232,504 million yen (YoY -9.6%), core operating profit 736 million yen, interim profit attributable to owners of parent 44,930 million yen. Full-year outlook unchanged from prior forecast. Dividend policy maintained at 40 yen at the end of the second quarter and 80 yen for the full year. Core adjustments include amortization of intangible assets and fair value inventory adjustments.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4528-20261029-01.pdf","jir_short_summary":"Interim consolidated results: Revenue 232,504 million yen (YoY -9.6%), core operating profit 736 million yen, interim profit attributable to owners of parent 44,930 million yen. Full-year outlook unchanged from prior forecast. Dividend policy maintained at 40 yen at the end of the second quarter and 80 yen for the full year. Core adjustments include amortization of intangible assets and fair value inventory adjustments.","jir_summary":"### Business Performance Overview\nIFRS-based revenue for the interim period amounted to 232,504 million yen (YoY -9.6%), affected by declines in product sales both domestically and internationally. On a core basis, core operating profit was 736 million yen and core interim profit was 56,800 million yen (year-on-year increase), illustrating divergences between IFRS and core measures. Supplementary presentation materials for the results are available.\n\n### Outlook and Dividends\nFull-year earnings guidance is maintained at the previously announced forecast. The dividend policy remains 40 yen at the end of the first quarter, 40 yen at the end of the second quarter, and 80 yen for the full year. The financial summary notes that, despite impacts such as the termination of the co-promotion agreement for Forxiga, the company plans to maintain stable overall cash flows.","jir_financial_highlights":"Revenue: 232,504 (YoY -9.6%)\nOperating Income: 57,907 (YoY +11.2%)\nProfit before tax (interim): 58,418 (YoY +12.0%)\nInterim Profit: 45,032 (YoY +12.1%)\nBasic Earnings per Share (interim): 95.60 (YoY +11.9 yen)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #Earnings, #IFRS, #InterimResults","jir_key_figures":"Revenue: 232,504 million yen\nOperating Income: 57,907 million yen\nInterim Profit: 45,032 million yen","jir_meta_title":"Ono Pharmaceutical Co., Ltd. \u2014 FY2027 Second Quarter Financial Summary | IFRS Consolidated","jir_meta_description":"Summary of Ono Pharmaceutical Co., Ltd.'s FY2027 second quarter financial summary (IFRS consolidated): Revenue 232,504 million yen (YoY -9.6%), Operating Income 57,907 million yen, dividend policy 80 yen full year, and key highlights.","jir_og_title":"Ono Pharmaceutical Co., Ltd. Announces Second Quarter Results | IFRS Consolidated","jir_og_description":"A summary of Ono Pharmaceutical Co., Ltd.'s FY2027 second quarter financial summary (IFRS), covering revenue and profit trends and dividend policy.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[257136,232504,232504]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[52069,57907,57907]}]}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Profit\\\",\\\"data\\\":[40089,45032]}]}}\"}, {\"jir_chart_id\": \"core_profit_margin\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Profit Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Interim Profit\\\",\\\"data\\\":[53.821,56.765]}]}}\"}, {\"jir_chart_id\": \"dividend_yield\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Dividend Policy\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Interim FY2026\\\",\\\"Interim FY2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Annual Dividend\\\",\\\"data\\\":[0,80]}]}}\"}]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-135979","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n